# US 2021/0163529 A1 · Method for Preparation of a Separation Matrix

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0163529 A1
- Document ID: US20210163529A1
- Status: Published application
- Kind: A1
- Application number: 16/955,119
- Filed: 2018-12-13
- Published: 2021-06-03
- Earliest claimed: 2017-12-20
- Assignees: Cytiva BioProcess R&D AB
- Applicants: Cytiva Bioprocess R&D AB
- Inventors: Gustav Rodrigo; Mats Ander; Ronnie Palmgren; Tomas Bjorkman
- Web page: https://patentgrep.com/patent/US20210163529A1

## CPC

- B01J 20/286: Phases chemically bonded to a substrate, e.g. to silica or to polymers
- C07K 1/22: Affinity chromatography or related techniques based upon selective absorption processes
- B01D 15/3809: {of the antigen-antibody type, e.g. protein A, G or L chromatography}
- B01J 20/24: Naturally occurring macromolecular compounds, e.g. humic acids or their derivatives
- B01J 20/28016: {Particle form}
- B01J 20/288: Polar phases
- B01J 20/3071: {Washing or leaching}
- B01J 20/3212: {consisting of a polymer obtained by reactions otherwise than involving only carbon to carbon unsaturated bonds}
- B01J 20/3217: {Resulting in a chemical bond between the coating or impregnating layer and the carrier, support or substrate, e.g. a covalent bond}
- B01J 20/3229: {for preventing leaching, leaking of attached functional or ligand groups}
- B01J 20/3274: {Proteins, nucleic acids, polysaccharides, antibodies or antigens}
- B01J 20/3295: {Coatings made of particles, nanoparticles, fibers, nanofibers}
- C07K 16/00: Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- B01J 2220/54: Sorbents specially adapted for analytical or investigative chromatography
- B01J: CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- B01D: SEPARATION (separating solids from solids by wet methods B03B, B03D; by pneumatic jigs or tables B03B; by other dry methods B07; magnetic or electrostatic separation of solid materials from solid materials or fluids, separation by high-voltage electric fields B03C; centrifuges, vortex apparatus B04; presses per se for squeezing-out liquid from liquid-containing material B30B9/02; treatment of water C02F, e.g. softening by ion-exchange C02F1/42; {arrangements of air intake cleaners in gas turbine plants F02C7/05} ; arrangements or mounting of filters in air-conditioning, air-humidification or ventilation F24F13/28)

## Abstract

A method for preparation of a separation matrix, comprising the steps of: a) providing a solid support and an alkali-stable ligand derived from an immunoglobulin-binding bacterial protein; b) reacting said alkali-stable ligand with said solid support to form a separation matrix having covalently coupled alkali-stable ligands; and c) washing said separation matrix having covalently coupled alkali-stable ligands with a wash solution comprising at least 10 mM of an alkali metal hydroxide.

## Claims

### Claim 1

A method for preparation of a separation matrix, comprising the steps of:
a) providing a solid support and an alkali-stable ligand derived from a bacterial immunoglobulin-binding protein;
b) reacting said alkali-stable ligand with said solid support to form a separation matrix having covalently coupled alkali-stable ligands; and
c) washing said separation matrix having covalently coupled alkali-stable ligands with a wash solution comprising at least 10 mM of an alkali metal hydroxide, such as NaOH or KOH or any mixture thereof.

### Claim 2 (depends on 1)

The method of claim 1, wherein said alkali-stable ligand derived from a bacterial immunoglobulin-binding protein is an alkali-stable Protein A ligand.

### Claim 3 (depends on 1)

The method of claim 1, wherein said alkali-stable ligand derived from a bacterial immunoglobulin-binding protein is an alkali-stable Protein L ligand.

### Claim 4 (depends on 1)

The method of claim 1, wherein said alkali-stable ligand derived from a bacterial immunoglobulin-binding protein is an alkali-stable Protein G ligand.

### Claim 5 (depends on 1)

The method of claim 1, wherein said solid support comprises a plurality of support particles, such as a plurality of porous support particles.

### Claim 6 (depends on 1)

The method of claim 1, wherein step c) is repeated at least once.

### Claim 7 (depends on 1)

The method of claim 1, wherein step c) is repeated at least 5 times.

### Claim 8 (depends on 1)

The method of claim 1, further comprising, after step c), a step d) of transferring said separation matrix to a storage solution.

### Claim 9 (depends on 8)

The method of claim 8, further comprising, after step d), a step of dispensing said separation matrix into transport containers.

### Claim 10 (depends on 1)

The method of claim 1, wherein step c) is performed within 24 h after step b).

### Claim 11 (depends on 1)

The method of claim 1, wherein in step c) the wash solution comprises 25 mM-1 M of an alkali metal hydroxide, such as NaOH or KOH or any mixture thereof.

### Claim 12 (depends on 1)

The method of claim 1, wherein in step c) the wash solution comprises 40 mM-1 M of an alkali metal hydroxide, such as 90 mM-0.5 M of an alkali metal hydroxide, or 50-200 mM of an alkali metal hydroxide.

### Claim 13 (depends on 1)

The method of claim 1, wherein in step c) the wash solution comprises 40 mM-1 M NaOH or KOH, such as 90 mM-0.5 M NaOH or KOH, or 50-200 mM NaOH or KOH.

### Claim 14 (depends on 1)

The method of claim 1, wherein in step c) the separation matrix is incubated with the wash solution during 2-60 min, such as 5-30 min.

### Claim 15 (depends on 14)

The method of claim 14, wherein, after incubation, the wash solution is removed by filtration.

### Claim 16 (depends on 1)

The method of claim 1, wherein in step c) the temperature is 2-40° C., such as 15-30° C. or 20-25° C.

### Claim 17 (depends on 1)

The method of claim 1, further comprising, before step b), a step a′) of activating said solid support.

### Claim 18 (depends on 17)

The method of claim 17, wherein step a′) comprises the formation of aldehyde groups on said solid support.

### Claim 19 (depends on 17)

The method of claim 17, wherein step a′) comprises the formation of epoxide groups on said solid support.

### Claim 20 (depends on 19)

The method of claim 19, wherein after step b), said separation matrix comprises residual epoxide groups.

### Claim 21 (depends on 15)

The method of claim 15, wherein the alkali-stable ligand derived from a bacterial immunoglobulin-binding protein comprises lysine residues capable of reacting with said aldehyde or epoxide groups.

### Claim 22 (depends on 19)

The method of claim 19, wherein the alkali-stable ligand derived from a bacterial immunoglobulin-binding protein comprises a cysteine residue with a thiol capable of reacting with said epoxide groups.

### Claim 23 (depends on 22)

The method of claim 22, wherein said cysteine residue is proximal to a C-terminus or an N-terminus of said alkali-stable ligand derived from a bacterial immunoglobulin-binding protein.

### Claim 24 (depends on 1)

The method of claim 1, wherein said alkali-stable ligand derived from a bacterial immunoglobulin-binding protein is capable of withstanding incubation with 0.1 M NaOH for 100×10 min at 22+/−2° C. with less than 45% reduction in binding capacity towards IgG.

### Claim 25 (depends on 1)

The method of claim 1, wherein said alkali-stable ligand derived from a bacterial immunoglobulin-binding protein is capable of withstanding incubation with 0.5 M NaOH for 100×10 min at 22+/−2° C. with less than 45% reduction in binding capacity towards IgG.

### Claim 26 (depends on 1)

The method of claim 1, wherein said alkali-stable ligand derived from a bacterial immunoglobulin-binding protein comprises at least one alkali-stable Protein A domain.

### Claim 27 (depends on 1)

The method of claim 1, wherein said alkali-stable ligand derived from a bacterial immunoglobulin-binding protein comprises a multimer of alkali-stable Protein A domains.

### Claim 28 (depends on 27)

The method of claim 27, wherein said multimer comprises at least four alkali-stable Protein A domains.

### Claim 29 (depends on 27)

The method of claim 27, wherein said multimer comprises at least six alkali-stable Protein A domains.

### Claim 30 (depends on 1)

The method of claim 1, wherein said alkali-stable ligand derived from a bacterial immunoglobulin-binding protein comprises at least one alkali-stable Protein L domain.

### Claim 31 (depends on 1)

The method of claim 1, wherein said alkali-stable ligand derived from a bacterial immunoglobulin-binding protein comprises a multimer of alkali-stable Protein A domains.

### Claim 32 (depends on 1)

The method of claim 1, wherein said alkali-stable ligand derived from a bacterial immunoglobulin-binding protein comprises at least one alkali-stable Protein G domain.

### Claim 33 (depends on 1)

The method of claim 1, wherein said alkali-stable ligand derived from a bacterial immunoglobulin-binding protein comprises a multimer of alkali-stable Protein G domains.

### Claim 34 (depends on 1)

The method of claim 1, wherein said solid support comprises a crosslinked polysaccharide.

### Claim 35 (depends on 1)

The method of claim 1, wherein said solid support comprises crosslinked agar or agarose.

### Claim 36 (depends on 1)

The method of claim 1, wherein said separation matrix comprises at least 11 mg covalently bound ligand per mL matrix, such as at least 15 mg covalently bound ligand per mL matrix

### Claim 37 (depends on 1)

The method of claim 1, wherein after step c), said separation matrix produces a ligand leakage of less than 40 ng ligand per mg IgG, as measured by an ELISA assay in an IgG eluate pool.

### Claim 38 (depends on 1)

The method of claim 1, which is a method of removing non-covalently bound Protein A ligand from the separation matrix.

### Claim 39 (depends on 38)

The method of claim 38, which is a method of removing non-covalently bound Protein A ligand from the separation matrix during preparation of the separation matrix.

### Claim 40 (depends on 1)

The method of any claim 1, which is a method of preparing a separation matrix comprising covalently coupled alkali-stable ligands derived from a bacterial immunoglobulin-binding protein and being substantially free from non-covalently coupled ligands derived from said bacterial immunoglobulin-binding protein.

### Claim 41 (depends on 1)

The method of claim 1, which is a method of preparing a separation matrix comprising covalently coupled alkali-stable Protein A ligands and being substantially free from non-covalently coupled Protein A ligands.

### Claim 42 (depends on 1)

The method of claim 1, which is a method of preparing a separation matrix comprising covalently coupled alkali-stable Protein L ligands and being substantially free from non-covalently coupled Protein L ligands.

### Claim 43 (depends on 1)

The method of claim 1, which is a method of preparing a separation matrix comprising covalently coupled alkali-stable Protein G ligands and being substantially free from non-covalently coupled Protein G ligands.
